Clinical trials: Healthy Control Subjects
Healthy Volunteers
A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants
The primary purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending oral doses of E6742 in Japanese healthy adult participants.
- Trial name
- NCT04683185
- Testing
- E6742
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Chronic Hepatitis B
A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects
A randomized study of ALG-125755 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics after single doses in healthy volunteers, and single and multiple doses in CHB subjects
- Trial name
- NCT05561530
- Testing
- ALG-125755
- Where
- 4 sites in Bulgaria, Moldova and 2 more
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Healthy, Asthma
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects
To investigate safety, tolerability, pharmacokinetics including posology, and pharmacodynamics of multiple rising doses of BI 1021958 in otherwise healthy mild asthmatic subjects
- Trial name
- NCT01629849
- Testing
- BI 1021958 bid, BI 1021958 qd
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- Boehringer Ingelheim
Healthy
Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects
Primary objective: Investigate the potential food effect on Adenosine diphosphate(ADP)-induced platelet aggregation after 5-day repeated doses of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) in healthy subjects…
- Trial name
- NCT01129271
- Testing
- clopidogrel
- Where
- 2 sites in United States, France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy
Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects
Study to assess the tolerability of an intravenous infusion of 0.5 and 1.0 mg (actual 0.8 mg) BIBT 986 BS per hour over 32 hours as well as pharmacokinetics and the effect on blood coagulation parameters
- Trial name
- NCT02254083
- Testing
- BIBT 986 BS - low, BIBT 986 BS - high
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers
To assess safety, pharmacokinetics and the effect of BIBR 1048 MS on coagulation parameters.
- Trial name
- NCT02170831
- Testing
- BIBR 1048 MS low, BIBR 1048 MS medium 1, BIBR 1048 MS medium 2
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatic Impairment
Pharmacokinetics of BAF312 in Patients With Hepatic Impairment
This study will investigate the pharmacokinetics of BAF312 in patients with mild, moderate and severe hepatic impairment compared to healthy control subjects.
- Trial name
- NCT01565902
- Testing
- BAF312
- Where
- 3 sites in Hungary, Russia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Asthma, Chronic Obstructive Pulmonary Disease COPD
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men
This is a randomized, single-blind, placebo-controlled, sequential-group study to assess the safety and tolerability as well as how the drug (AZD7594) affects the body (pharmacodynamics [PD]) and how the body affects the drug…
- Trial name
- NCT02645253
- Testing
- AZD7594 inhalation powder (200 μg), AZD7594 inhalation powder (400 μg), AZD7594 pressurized inhalation suspension (200 μg)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Stroke
Single and Repeat Doses of DMT in Healthy Subjects
This study aims to assess the safety and tolerability of single ascending, and fixed repeated doses of N,N-Dimethyltryptamine (DMT) in healthy subjects, when given by intravenous (IV) infusion.
- Trial name
- NCT05559931
- Testing
- N,N-Dimethyltryptamine
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Algernon Pharmaceuticals
Worsening Chronic Heart Failure, Chronic Kidney Disease
A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should.
- Trial name
- NCT04908436
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Participants
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Effect of Food of SYH2056 in Healthy Subjects
This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK characteristics, and food effect of single ascending oral doses of SYH2056 tablets in healthy participants.
- Trial name
- NCT07771777
- Testing
- SYH2056 tablets
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- InnovStone Therapeutics Limited
Depressive Disorder
Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects
The primary purpose of this study is to compare the steady-state pharmacokinetic profile of paroxetine CR (controlled-release) at the dosage of 25mg/day using the proposed final market tablet of CR 25mg in Japan with that of…
- Trial name
- NCT01000857
- Testing
- Paroxetine CR and Paroxetine IR
- Where
- Japan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Renal Impairment
A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers
The purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of pasireotide,the PK of pasireotide in subjects with different degrees of renal impairment.
- Trial name
- NCT01578928
- Testing
- SOM230
- Where
- 2 sites in Germany, South Africa
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Safety Issues, Tolerability
SB17170 Phase1 Trial in Healthy Volunteer
This clinical trial aims to learn about the safety, tolerability, and pharmacokinetic properties of SB17170 and its active metabolite SB1703 in single and multiple oral administration in healthy adults.
- Conditions
- Safety Issues, Tolerability, Pharmacokinetics, Pharmacodynamics
- Trial name
- NCT05795192
- Testing
- SB17170
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- SPARK Biopharma
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Influenza
Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain
The purpose of this study are to determine the effect FF-3 in comparison to placebo in subjects who are experimentally inoculated with a live, challenge strain of influenza A virus.
- Trial name
- NCT02423577
- Testing
- FF-3 dry powder
- Where
- United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Autoimmune Technologies, LLC
Healthy
Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years of age
- Trial name
- NCT01005407
- Testing
- Engerix-B
- Where
- 32 sites in United States, Canada
- Volunteers
- 2,452 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Hepatitis B, Chronic
A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531
This sponsor-open, investigator- and participant-blinded, multi-center study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy participants and in participants with chronic…
- Trial name
- NCT02956850
- Testing
- RO7020531
- Where
- 18 sites in Bulgaria, Hong Kong and 6 more
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects
Phase 1, randomized, double-blind, placebo-controlled first-in-human study to investigate the safety, tolerability, PK and PD properties of single ascending intravenous (IV) and subcutaneous (SC) doses of KPL-404 in healthy…
- Trial name
- NCT04497662
- Testing
- KPL-404
- Where
- 2 sites in United States, Australia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Kiniksa Pharmaceuticals, Ltd.
Asthma
XKH001 Injection in Healthy Subjects
This study is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) clinical study. The primary objective is to evaluate the safety, tolerability, and PK of multiple SC doses of XKH001 in healthy subjects.
- Trial name
- NCT05991661
- Testing
- XKH001 Injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Beijing Kanova Biopharmaceutical Co., LTD